Literature DB >> 17503662

Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.

Angel Moreno-Torres1, Pere Domingo, Jesus Pujol, Francisco Blanco-Vaca, Juan Antonio Arroyo, M Antonia Sambeat.   

Abstract

OBJECTIVE: To carry out an exploratory evaluation of liver triglyceride content in HIV-1-infected patients receiving highly active antiretroviral therapy (HAART) using proton magnetic resonance spectroscopy and to study how both the treatment itself and the biochemical and physiological variables in which the treatment causes alterations are related to liver fat content.
METHODS: Intracellular hepatic triglyceride content was determined in 29 HIV-1-infected patients on their first HAART regime by means of localized water-unsuppressed single voxel proton spectra. Other measurements were body mass index, waist-to-hip ratio, lipodystrophy assessment and a detailed blood biochemical analysis. The relationship between intracellular hepatic triglycerides and relevant descriptive, treatment and biochemical variables was studied by correlation and regression analysis.
RESULTS: Intrahepatic triglycerides were detected in 58.6% of the patients and 13.8% showed a triglyceride content compatible with liver steatosis. Many variables (body mass index, waist-to-hip ratio, cumulative exposure to PIs, lactate, insulin, insulin resistance measured by the homeostasis model assessment method [HOMA-R index], pH, total triglycerides, high density lipoprotein cholesterol and very low density lipoprotein [VLDL] cholesterol) correlated individually with the amount of triglycerides. Stepwise multiple regression analysis showed that the combination of insulin or HOMA-R index and VLDL cholesterol accounted for up to 50.2% of the triglyceride liver variance. A positive relationship was found between the concomitant presence of the metabolic syndrome components (insulin resistance, dyslipidaemia and central obesity) and intrahepatic triglyceride content.
CONCLUSIONS: The study showed that intrahepatic triglyceride deposit appears to be a frequent feature of HIV-1-infected patients receiving HAART. A coherent multifactorial combination of biochemical and physiological factors associated with the deposit suggested that cumulative exposure to PIs might be a possible trigger event.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17503662

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  6 in total

Review 1.  Obesity and Weight Gain in Persons with HIV.

Authors:  Samuel S Bailin; Curtis L Gabriel; Celestine N Wanjalla; John R Koethe
Journal:  Curr HIV/AIDS Rep       Date:  2020-04       Impact factor: 5.071

2.  Cocaine use may modify HIV/ART-associated myocardial steatosis and hepatic steatosis.

Authors:  Shenghan Lai; Gary Gerstenblith; Richard D Moore; David D Celentano; David A Bluemke; Glenn Treisman; Chia-Ying Liu; Ji Li; Shaoguang Chen; Thomas Kickler; Hong Lai
Journal:  Drug Alcohol Depend       Date:  2017-05-26       Impact factor: 4.492

3.  Uridine metabolism in HIV-1-infected patients: effect of infection, of antiretroviral therapy and of HIV-1/ART-associated lipodystrophy syndrome.

Authors:  Pere Domingo; Javier Torres-Torronteras; Virginia Pomar; Marta Giralt; Joan Carles Domingo; Maria Del Mar Gutierrez; José M Gallego-Escuredo; Maria Gracia Mateo; Pedro Cano-Soldado; Irene Fernandez; Marçal Pastor-Anglada; Francesc Vidal; Francesc Villarroya; Antoni Andreu; Ramon Marti
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

4.  HIV and HAART-Associated Dyslipidemia.

Authors:  Eoin R Feeney; Patrick W G Mallon
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

5.  Insulin resistance, hepatic lipid and adipose tissue distribution in HIV-infected men.

Authors:  Qing He; Ellen S Engelson; Gabriel Ionescu; Marshall J Glesby; Jeanine B Albu; Donald P Kotler
Journal:  Antivir Ther       Date:  2008

6.  PPAR and liver injury in HIV-infected patients.

Authors:  Maud Lemoine; Jacqueline Capeau; Lawrence Serfaty
Journal:  PPAR Res       Date:  2009-04-15       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.